Kamada (NASDAQ:KMDA) Research Coverage Started at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Kamada (NASDAQ:KMDA) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Kamada in a research note on Thursday, May 9th.

Kamada Stock Performance

Shares of NASDAQ KMDA opened at $4.96 on Thursday. Kamada has a fifty-two week low of $4.08 and a fifty-two week high of $6.53. The company has a market cap of $285.10 million, a PE ratio of 21.57 and a beta of 1.06. The business has a 50-day simple moving average of $5.27 and a two-hundred day simple moving average of $5.63.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.02). The company had revenue of $37.74 million during the quarter, compared to analysts’ expectations of $38.01 million. Kamada had a net margin of 8.33% and a return on equity of 5.50%. On average, sell-side analysts predict that Kamada will post 0.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Kamada by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after buying an additional 100,800 shares during the last quarter. Aristides Capital LLC lifted its stake in Kamada by 41.6% during the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after acquiring an additional 16,635 shares during the period. Y.D. More Investments Ltd boosted its holdings in shares of Kamada by 107.1% in the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 15,000 shares during the last quarter. Calton & Associates Inc. purchased a new stake in shares of Kamada in the 4th quarter valued at $111,000. Finally, EWA LLC acquired a new stake in shares of Kamada in the fourth quarter worth $68,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.